← Home / Summit Therapeutics Inc. (SMMT)
Stock Analysis
Summit Therapeutics Inc. (SMMT)
SMMT
SMMT · Market data
13.44 -4.04%
Track SMMT in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when SMMT price is:
52W Range Position
6%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-14 17:46 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Weak / Insufficient
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
14.24
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
23
↗
Equity Offering / Capital Raise
HIGH
SMMT equity financing update
On July 23, 2026, Summit Therapeutics Inc.
8-K Filing • SEC EDGAR
JUL
23
●
Financial Results
HIGH
Summit Therapeutics Inc. Schedule Reconciling Selected Non-GAAP Financial Measures (in millions) Unaudited Three Months Ended June 30, 2026 March 31, 2026 December 31, 2025 September 30, 2025 June 30, 2025 Reconciliation
a2026_prx0723xq22026earn Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Pl...
8-K Filing • SEC EDGAR
JUL
23
●
Material Agreement
HIGH
SMMT material agreement
On July 23, 2026, Summit Therapeutics Inc.
8-K Filing • SEC EDGAR
What's Driving SMMT?
📈 Technical recovery is improving
Momentum is Neutral. Watch 14.24 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
Pattern
Triangle Compression / SYM / DOWN
State
Forming
Compression
25%
RSI(14)
43.9
◎
How to read this setup
Pattern note: compression remains elevated around 25%, which means breakout quality matters more than noise inside the pattern.
Price Chart
SMMT — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-13
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$11.1B
Company size
EV
$10.7B
Debt-adjusted value
P/E
-13.0
Not meaningful
P/B
17.6
Premium
EV/EBIT
-47.2
Not meaningful
P/FCF
-24.2
Not meaningful
FCF Yield
-4.14%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Insufficient
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
0.00
↘ Weak
📈 Net Income
-215.70M
≈ Insufficient
🧮 EPS (Basic)
-0.28
≈ Insufficient
Summit Therapeutics Inc.
Related Opportunities